Spots Global Cancer Trial Database for acute myeloid leukemia (aml)
Every month we try and update this database with for acute myeloid leukemia (aml) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | NCT02421939 | Leukemia, Acute... | gilteritinib LoDAC (Low Dose... Azacitidine MEC (Mitoxantro... FLAG-IDA (Granu... | 18 Years - | Astellas Pharma Inc | |
| Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies. | NCT03218683 | Relapsed or Ref... | AZD5991 AZD5991 + Venet... | 18 Years - 85 Years | AstraZeneca | |
| Safety Study of 5-Azacitidine and Standard Donor Lymphocyte Infusion (DLI) to Treat Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) Relapsing After Allogeneic Stem Cell Transplantation | NCT00795548 | Myelodysplastic... Acute Myeloid L... | 5-Azacitidine | 18 Years - | Heinrich-Heine University, Duesseldorf | |
| Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological Malignancies | NCT03263637 | Relapsed or Ref... Acute Myeloid L... Acute Lymphocyt... Chronic Lymphoc... High Risk Myelo... Chronic Myelomo... Richter's Syndr... B-cell Non-Hodg... T-cell Non-Hodg... Small Lymphocyt... Multiple Myelom... | AZD4573 | 18 Years - 130 Years | AstraZeneca | |
| Peptide Vaccinations to Treat Patients With Low-Risk Myeloid Cancers | NCT00488592 | Myelodysplastic... Acute Myeloid L... Chronic Myeloid... | WT1:126-134 PR1:169-177 Pep... GM-CSF (Sargram... Montanide adjuv... | 18 Years - 85 Years | National Institutes of Health Clinical Center (CC) | |
| Selinexor With Fludarabine and Cytarabine for Treatment of Refractory or Relapsed Leukemia or Myelodysplastic Syndrome | NCT02212561 | Acute Myeloid L... Acute Lymphobla... Myelodysplastic... Mixed Phenotype... | Selinexor Fludarabine Cytarabine methotrexate/hy... | - 24 Years | St. Jude Children's Research Hospital | |
| A Study of Oral Venetoclax Tablet in Combination With Subcutaneous Low-Dose Cytarabine (LDAC) Injection to Assess Adverse Events in Adult Japanese Participants With Acute Myeloid Leukemia (AML) | NCT04509622 | Acute Myeloid L... | Venetoclax Cytarabine | 18 Years - | AbbVie | |
| Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler | NCT01463410 | Acute Myeloid L... Acute Promyeloc... Refractory Anem... | 18 Years - | Skyline Diagnostics BV | ||
| Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML | NCT01191957 | Acute Myeloid L... | Busulphan plus ... Busulphan plus ... | 40 Years - 65 Years | Gruppo Italiano Trapianto di Midollo Osseo | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc | |
| Safety and Effectiveness Study of CPI-613 to Treat Refractory or Relapsed Leukemia and Myelodysplastic Syndrome | NCT01520805 | Acute Myeloid L... Myelodysplastic... | CPI-613 | 18 Years - | Cornerstone Pharmaceuticals | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| Treatment of Elderly AML Patients With Induction Chemotherapy Followed by G-CSF-Mobilized Stem Cells From Haploidentical Related Donors | NCT02519712 | Acute Myeloid L... | Induction Chemo... G-PBSC Infusion | 60 Years - | Memorial Sloan Kettering Cancer Center | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| KIR Favorable Mismatched Haplo Transplant and KIR Polymorphism in ALL/AML/MDS Allo-HCT Children | NCT02646839 | Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | CliniMacs TCR a... | - 21 Years | Children's Hospital Los Angeles | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients | NCT01929408 | Acute Myeloid L... Myelodysplastic... | 18 Years - 80 Years | Fred Hutchinson Cancer Center | ||
| Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML) | NCT00890929 | Acute Myeloid L... Adult Acute Mye... | Lenalidomide Azacitidine | 60 Years - | Stanford University | |
| Safety & Efficacy Study of Oral Panobinostat (LBH589) With Chemotherapy in Patients < 65 Years Old With Acute Myeloid Leukemia (AML) | NCT01242774 | Acute Myeloid L... | Panobinostat | 18 Years - 65 Years | Novartis | |
| Phase II Study of 5-azacytidine Maintenance After Transplant for AML or MDS | NCT02204020 | Acute Myeloid L... Myelodysplastic... | 5-azacytidine (... | 18 Years - | University of Pittsburgh | |
| Study of Oral Venetoclax Tablets to Evaluate Adverse Events and Change in Disease Activity in Participants of Any Age With Acute Myeloid Leukemia | NCT04813263 | Acute Myeloid L... | - | AbbVie | ||
| Study of Orally Administered AG-881 in Patients With Advanced Hematologic Malignancies With an IDH1 and/or IDH2 Mutation | NCT02492737 | Acute Myeloid L... Myelodysplastic... Hematologic Mal... | AG881 | 18 Years - | Agios Pharmaceuticals, Inc. | |
| Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | NCT04402723 | Acute Myeloid L... | Donafenib | 18 Years - 55 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Molecular Diagnostic Platform for AML | NCT04446741 | Acute Myeloid L... | 18 Years - 99 Years | PETHEMA Foundation | ||
| A Study Evaluating the Safety, Tolerability, Pharmacokinetics and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors | NCT04029688 | Acute Myeloid L... Acute Lymphobla... Neuroblastoma Solid Tumors | Idasanutlin Venetoclax Cyclophosphamid... Topotecan Fludarabine Cytarabine Intrathecal Che... | 0 Years - 30 Years | Hoffmann-La Roche | |
| Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | NCT01237808 | Acute Myeloid L... | Cytarabine Etoposide All-trans retin... | 61 Years - | University of Ulm | |
| A Study to Assess Safety and Efficacy of Venetoclax in Combination With Gilteritinib in Participants With Relapsed/Refractory Acute Myeloid Leukemia | NCT03625505 | Acute Myeloid L... | Venetoclax Gilteritinib | 18 Years - | AbbVie | |
| Injection of Lymphocytes From Haplo-identical Donor Following Chemotherapy in Patients With High-risk Acute Myeloblastic Leukemia Not Eligible for an Allogeneic Hematopoietic Stem Cell Transplantation | NCT04886206 | Acute Myeloid L... | DLI | 18 Years - | Nantes University Hospital | |
| Leukemic Dendritic Cell Vaccination in Patients With Acute Myeloid Leukemia | NCT01373515 | Acute Myeloid L... Leukemic Dendri... | DCP-001 | 18 Years - 80 Years | Mendus | |
| A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy | NCT02752035 | Acute Myeloid L... Acute Myeloid L... | gilteritinib azacitidine | 18 Years - | Astellas Pharma Inc | |
| Leukemia Stem Cell Detection in Acute Myeloid Leukemia | NCT02927938 | Acute Myeloid L... | Allogeneic HCT Consolidation c... | 18 Years - | Wake Forest University Health Sciences | |
| Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With Newly Diagnosed Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) | NCT00666497 | Acute Myeloid L... Myelodysplastic... | Azacitidine MGCD0103 MGCD0103 | 60 Years - | Mirati Therapeutics Inc. | |
| A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy | NCT03069352 | Acute Myeloid L... | Placebo Venetoclax Cytarabine | 18 Years - | AbbVie | |
| GEN3014 Safety Trial in Relapsed or Refractory Hematologic Malignancies | NCT04824794 | Relapsed or Ref... Diffuse Large B... Acute Myeloid L... | GEN3014 Daratumumab | 18 Years - | Genmab | |
| Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | NCT00809276 | Lymphoma Multiple Myelom... Leukemia Myelodysplastic... | Busulfan, Fluda... | - 65 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Allogenic Stem Cell Transplantation for Children, Adolescents and Young Adults With Relapsed or Refractory AML | NCT00606723 | Acute Myeloid L... | Hematopoietic s... | - 21 Years | Hannover Medical School | |
| An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy. | NCT05907057 | Acute Myeloid L... | Ivosidenib 500m... Azacitidine | 18 Years - | Servier | |
| Haplo-identical Natural Killer (NK) Cells to Prevent Post-Transplant Relapse in AML and MDS (NK-REALM) | NCT04395092 | Acute Myeloid L... Myelodysplastic... | K-NK002 Conditioning Re... HaploBMT | 18 Years - 65 Years | Kiadis Pharma | |
| A Dose Finding Study of IDH305 With Standard of Care in IDH1 Mutant Acute Myeloid Leukemia | NCT02826642 | Acute Myeloid L... | IDH305 | 18 Years - | Novartis | |
| Busulfan (BU) Plus Fludarabine Vs Intravenous BU Plus Cyclophosphamide as Conditioning Regimens Prior Allogeneic Hematopoetic Stem Cells Transplant (HSCT) in AML | NCT01191957 | Acute Myeloid L... | Busulphan plus ... Busulphan plus ... | 40 Years - 65 Years | Gruppo Italiano Trapianto di Midollo Osseo | |
| Study of the Glutaminase Inhibitor CB-839 in Leukemia | NCT02071927 | Acute Myeloid L... Acute Lymphocyt... | CB-839 CB-Aza | 18 Years - | Calithera Biosciences, Inc | |
| Yoga Fatigue Study | NCT02134782 | Acute Myeloid L... Acute Lymphocyt... Burkitt's Lymph... Burkitt's Lymph... Type 3 Diffuse ... | Individualized ... iPad Activity C... | 8 Years - 18 Years | The Hospital for Sick Children | |
| Accuracy Testing of the Chromosomal Aberration and Gene Mutation Markers of the AMLProfiler | NCT01463410 | Acute Myeloid L... Acute Promyeloc... Refractory Anem... | 18 Years - | Skyline Diagnostics BV | ||
| A Study of Midostaurin Efficacy and Safety in Newly Diagnosed Patients With FLT3-mutated AML | NCT03280030 | Acute Myeloid L... | Midostaurin Placebo | 18 Years - 70 Years | Novartis | |
| A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer | NCT02391480 | Cancer Breast Cancer Non-Small Cell ... Acute Myeloid L... Multiple Myelom... Prostate Cancer Small Cell Lung... Non-Hodgkins Ly... | ABBV-075 Venetoclax | 18 Years - | AbbVie | |
| Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of ASP2215 in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia | NCT02181660 | Acute Myeloid L... | Gilteritinib | 18 Years - | Astellas Pharma Inc | |
| Oral Histone Deacetylase Inhibitor 4SC-202 in Patients With Advanced Hematologic Malignancies (TOPAS) | NCT01344707 | Advanced Hemato... | 4SC-202 | 18 Years - | 4SC AG | |
| A Study Evaluating Safety and Efficacy of Venetoclax in Combination With Azacitidine Versus Standard of Care After Allogeneic Stem Cell Transplantation (SCT) in Participants With Acute Myeloid Leukemia (AML) | NCT04161885 | Acute Myeloid L... Cancer | Venetoclax Azacitidine Best Supportive... | 12 Years - | AbbVie | |
| Ivosidenib (TIBSOVO®) Combined With Azacitidine According to Current SmPC | NCT06181734 | Acute Myeloid L... | Ivosidenib | 18 Years - | iOMEDICO AG | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| Trial Evaluating Induction Therapy With Idarubicin and Etoposide Plus Sequential or Concurrent Azacitidine and Maintenance Therapy With Azacitidine | NCT01180322 | Acute Myeloid L... | Cytarabine Idarubicin Etoposide Azacitidine Lenograstim | 18 Years - | University of Ulm | |
| A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously-Treated Solid Tumors and Hematologic Malignancies | NCT03082209 | Advanced Solid ... Cancer Hematologic Mal... | ABBV-621 Venetoclax Bevacizumab FOLFIRI | 18 Years - | AbbVie | |
| Clinical Trial of BP1001 in Combination With With Venetoclax Plus Decitabine in AML | NCT02781883 | Acute Myeloid L... | BP1001 in combi... BP1001 plus dec... | 18 Years - | Bio-Path Holdings, Inc. | |
| Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies | NCT00145613 | Acute Lymphobla... Acute Myeloid L... Secondary AML Myelodysplastic... Secondary MDS Chronic Myeloid... Juvenile Myelom... Paroxysmal Noct... Lymphoma, Non-H... Hodgkin Disease | Stem Cell Trans... Miltenyi Biotec... Systemic chemot... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Combination of Donafenib and Cytarabine/Daunorubicin in Relapsed AML | NCT04402723 | Acute Myeloid L... | Donafenib | 18 Years - 55 Years | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | |
| Study of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 Mutation | NCT01237808 | Acute Myeloid L... | Cytarabine Etoposide All-trans retin... | 61 Years - | University of Ulm | |
| A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers | NCT04272203 | Acute Myeloid L... Non Small Cell ... Cancer | ABBV-184 | 18 Years - | AbbVie | |
| Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) | NCT01147939 | Acute Myeloid L... | Elacytarabine Investigator's ... | 18 Years - | Clavis Pharma | |
| A Phase Ib Study of CT053PTSA in Relapsed / Refractory Acute Myeloid Leukemia (AML) | NCT03125876 | Acute Myeloid L... | CT053PTSA | 18 Years - 65 Years | Sunshine Lake Pharma Co., Ltd. | |
| A Study of the Effectiveness of Venetoclax in Combination With Azacitidine or Decitabine in an Outpatient Setting in Patients With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy | NCT03941964 | Acute Myeloid L... Cancer | Venetoclax Azacitidine Decitabine | 12 Years - | AbbVie | |
| Study of BMS-986497 (ORM-6151) in Participants With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome | NCT06419634 | Acute Myeloid L... Myelodysplastic... | BMS-986497 | 18 Years - | Bristol-Myers Squibb | |
| Treosulfan/Fludarabine/Low Dose TBI as a Preparative Regimen for Children With AML/MDS Undergoing Allo HCT | NCT01772953 | Acute Myeloid L... Myelodysplastic... | Treosulfan | - 21 Years | Center for International Blood and Marrow Transplant Research | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| Pharmacokinetics, Tolerability and Safety of NEX-18a | NCT05048498 | Myelodysplastic... Chronic Myelomo... Acute Myeloid L... | NEX-18a injecti... Azacitidine Inj... | 18 Years - | Nanexa AB | |
| PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | NCT00093600 | Acute Myeloid L... | cytarabine daunorubicin hy... midostaurin | 18 Years - 60 Years | Novartis | |
| Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML | NCT00568633 | Leukemia, Myelo... Leukemia Acute Myeloid L... | Allogeneic HSCT Anti-thymocyte ... Cyclosporine (C... Mycophenolate m... Total lymphoid ... Methylprednisol... Best standard c... | 50 Years - 75 Years | Stanford University | |
| Safety, Tolerability and Pharmacokinetics of CSL360 in the Treatment of Acute Myeloid Leukemia | NCT00401739 | Acute Myeloid L... | CSL360 | 18 Years - | CSL Limited | |
| A Three-part Study of Eltrombopag in Thrombocytopenic Subjects With Myelodysplastic Syndromes or Acute Myeloid Leukemia | NCT01440374 | Thrombocytopaen... | eltrombopag placebo | 18 Years - 110 Years | Novartis | |
| Dendritic Cell Vaccination for Patients With Acute Myeloid Leukemia in Remission | NCT00834002 | Acute Myeloid L... | injection of an... | 18 Years - | University Hospital, Antwerp | |
| Leukemia Stem Cell Detection in Acute Myeloid Leukemia | NCT02927938 | Acute Myeloid L... | Allogeneic HCT Consolidation c... | 18 Years - | Wake Forest University Health Sciences | |
| Study Evaluating Sorafenib Added to Standard Primary Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Less Than 60 Years of Age | NCT00893373 | Acute Myeloid L... | sorafenib placebo | 18 Years - 60 Years | Technische Universität Dresden | |
| Dose Escalation Study of CAL-101 in Select Relapsed or Refractory Hematologic Malignancies | NCT00710528 | Chronic Lymphoc... Lymphoma, Non-H... Acute Myeloid L... Multiple Myelom... | CAL-101 | 18 Years - | Gilead Sciences | |
| VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma) | NCT04702425 | Non-Hodgkin Lym... Acute Myeloid L... Multiple Myelom... | VOB560 MIK665 | 18 Years - | Novartis | |
| Study of Quizartinib in Combination With Standard Therapies in Chinese Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) | NCT03723681 | Acute Myeloid L... | Quizartinib | 18 Years - 70 Years | Daiichi Sankyo | |
| A Study of Oral Venetoclax Tablets and Oral Azacitidine Versus Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy | NCT04102020 | Acute Myeloid L... | Venetoclax Azacitidine CC-486 | 18 Years - | AbbVie | |
| A Study of ASP2215 (Gilteritinib) Combined With Atezolizumab in Patients With Relapsed or Treatment Refractory FMS-like Tyrosine Kinase (FLT3) Mutated Acute Myeloid Leukemia (AML) | NCT03730012 | Acute Myeloid L... Acute Myeloid L... | gilteritinib atezolizumab | 18 Years - | Astellas Pharma Inc | |
| Study of CPX-351 (VYXEOS) in Individuals < 22 Years With Secondary Myeloid Neoplasms | NCT05656248 | Myeloid Neoplas... | CPX-351 MHA Allogeneic Hema... | 1 Year - 21 Years | St. Jude Children's Research Hospital | |
| Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Cells, in Patients With HM | NCT01816230 | Hematological M... Acute Lymphobla... Acute Myeloid L... Myelodysplastic... | NiCord® | 12 Years - 65 Years | Gamida Cell ltd | |
| A Study of Voruciclib Alone or in Combination With Venetoclax in Subjects With B-Cell Malignancies or AML | NCT03547115 | Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Small Lymphocyt... Chronic Lymphoc... Diffuse Large B... Acute Myeloid L... | voruciclib mono... voruciclib and ... | 18 Years - | MEI Pharma, Inc. | |
| A Study of Gilteritinib, Venetoclax and Azacitidine as a Combined Treatment for People Newly Diagnosed With Acute Myeloid Leukemia | NCT05520567 | Acute Myeloid L... FLT3-mutated Ac... | Gilteritinib Venetoclax Azacitidine | 18 Years - | Astellas Pharma Inc |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
